haematology general-medicine
IMPROVE-DD VTE Risk Score
Predicts VTE risk in medically ill hospitalised patients. The IMPROVE-DD version adds D-dimer to the original IMPROVE score.
Score interpretation
Low Risk 0–1
Low VTE risk (<1% at 14 days)
→ No pharmacological prophylaxis needed
Intermediate Risk 2–3
Intermediate VTE risk
→ Consider prophylaxis
High Risk 4–16
High VTE risk (≥2% at 14 days)
→ Pharmacological prophylaxis recommended (LMWH/UFH)
Interpretation bands for the IMPROVE-DD. Apply clinical judgement and local guidance.
References
- Gibson CM et al. Prevention of VTE in hospitalized patients with acute medically ill conditions with betrixaban. N Engl J Med. 2016;375(6):534–544.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Anti-D (Rh₀) Immunoglobulin · Immunoglobulin (Rh Prophylaxis)
- Cefuroxime · Second-Generation Cephalosporin — Respiratory / Surgical Prophylaxis
- Benzathine Benzylpenicillin · Long-Acting Penicillin — Syphilis / Rheumatic Fever Prophylaxis
- Micafungin · Echinocandin Antifungal — Invasive Candidiasis / Prophylaxis in HSCT
- Posaconazole · Extended-Spectrum Triazole — Aspergillus / Mucor / Prophylaxis in Immunocompromised
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.